It’s an R&D accelerant. It shortens feedback loops. It reveals flaws early.

Parkinson’s Disease: A Mini-Review of Clinical Pharmacology. 2006 . (4)         Garcia-Borreguero, D. 2018 , 839 , 40–46. https://doi.org/10.1016/j.ejphar.2018.09.008 . (8)         Rinken, A.; Lavogina, D. D.; Hanada, K.; Pagano, R. E.; Miller, L. J. -J.; Kopanchuk, S.; Laasfeld, T.; Weinhart, M.; Schollmeyer, D.; Betschart, M.

Highlights: • The Foundry Arrives : R&D meets biotech with real-world acceleration, strategic consulting

endosomes and other organelles. eLife. 2024 Nov 8; 13:RP97033. doi: 10.7554/eLife.97033.3   Maurel D,

adenocarcinoma: p = 0.004, mesothelioma: p = 0.039, ovarian serous cystadenocarcinoma: p = 0.048); (d)

one sustained curiosity thread involved a protein released by alpha cells in the pancreas: Vitamin D

Comparative evaluation of biased agonists Sarcosine1 , d-Alanine8 -Angiotensin (Ang) II (SD Ang II) and GPCRs in Oncology and Immunology LP2, a cyclic angiotensin-(1-7) analog extended with an N-terminal D-lysine

currents GPCR Binders, Drugs, and more LP2, a cyclic angiotensin-(1-7) analog extended with an N-terminal D-lysine

Career opportunities:  Senior Scientist, Phage Display | Manager, CMC Management | Translational R&D

Miranda-Pastoriza D, Bernárdez R, Azuaje J, Prieto-Díaz R, Majellaro M, Tamhankar AV, Koenekoop L, González

is strategic, method-proven insight for discovery teams, pharmacologists refining core skills, and R&D

startup environments Read Maria Majellaro's Full Recap ➤ Lab Leadership Without Ego: A Model for R&D

Hilger, D., et al., Structural insights into differences in G protein activation by family A and family

For Hodson, that moment came with a protein he’d been tracking for a decade: vitamin D binding protein

GPCR Foundry  — our R&D and biotech hub designed to bridge GPCR science with execution. The Dr.

do: bring four decades of frontline discovery insight straight to discovery-phase scientists and R&D

Every R&D team is under the same pressure: deliver validated targets, clean pharmacology, and translatable

on Smooth operator(s): dialing up and down neurotransmitter responses by G-protein regulators András D

Receives US$10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D

GPCR Activation and Signaling Statins inhibit protein kinase D (PKD) activation in intestinal cells and

Wootten, D., et al., The Extracellular Surface of the GLP-1 Receptor Is a Molecular Trigger for Biased

G-protein and GPCR signaling reveals unexpected differences in downstream pathway activation Chiara D

Structural and Molecular Insights into GPCR Function Endogenous l- to d-amino acid residue isomerization

Jurado, S., D. Goswami, Y. Zhang, A.J.M. Molina, T.C. Südhof, and R.C. Malenka. 2013.

from September 30th to October 6th, 2024 Industry News Nxera Pharma appoints experienced commercial R&D

First Protein Structures in PDB, Advances Lupus Therapy Research Structure Therapeutics Receives R&D

Scribble scrambles parathyroid hormone receptor interactions to regulate phosphate and vitamin D homeostasis

This Week’s Highlights: G protein-coupled receptor (GPCR) pharmacogenomics Miles D Thompson , David

Wang, D., The essential role of G protein-coupled receptor (GPCR) signaling in regulating T cell immunity

, 344 (3), 708–717. https://doi.org/10.1124/jpet.112.201616 Violin, J.D., DeWire, S.M., Yamashita, D.